Investment Summary

Arlington Capital Partners Invests In Everest Clinical Research

On December 7, 2020, private equity firm Arlington Capital Partners invested in life science company Everest Clinical Research

Investment Highlights
  • This is Arlington Capital Partners’ 3rd transaction in the Life Science sector.
  • This is Arlington Capital Partners’ 1st transaction in Canada.
  • This is Arlington Capital Partners’ 1st transaction in Ontario.

Investment Summary
Date 2020-12-07
Target Everest Clinical Research
Sector Life Science
Investor(s) Arlington Capital Partners
Deal Type Growth Capital

Target

Everest Clinical Research

Markham, Ontario, Canada
Everest Clinical Research is a contract research organization (“CRO”) providing a comprehensive suite of mission-critical clinical research services to the worldwide pharmaceutical, biotechnology, and medical device industries across Phase I-IV trials. Everest Clinical Research was founded in 2004 and is based in Markham, Ontario.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Arlington Capital Partners

Chevy Chase, Maryland, United States

Investor Investor Investor Investor Investor

Category Private Equity Firm
Founded 1999
PE ASSETS 7.0B USD
Size Large
Type Sector Agnostic
DESCRIPTION

Arlington Capital Partners is a middle-market private equity firm focused on buyouts and recapitalizations in targeted growth industries. Arlington targets US based companies valued between $50 and $500 million with strong potential for organic growth and possible consolidation opportunities. Sectors of interest include business services and outsourcing, aerospace/defense, federal and commercial IT, media, education and training, healthcare services, and manufacturing. Arlington Capital was formed in 1999 and is headquartered in Washington DC.

DEAL STATS #
Overall 50 of 64
Sector (Life Science) 3 of 4
Type (Growth Capital) 5 of 5
State (Ontario) 1 of 1
Country (Canada) 1 of 1
Year (2020) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-08-19 Centauri

Chantilly, Virginia, United States

Centauri is a technology-driven company providing high-end, creative software and engineering solutions to critical national security missions across space, cyber, ISR, missile defense, and intelligence domains.

Sell $827M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-07 Molecular Products

Harlow, United Kingdom

Molecular Products is a manufacturer of advanced chemistry-based products serving the healthcare, defense, and industrial markets. The Company primarily specializes in the manufacture and supply of chemical technologies for the treatment of breathable gases. Molecular Products was founded in 1924 and is based in Harlow, United Kingdom.

Sell -
Mergr

Product

Company

Legal